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Chorioamnionitis is associated with significant maternal and neonatal morbidity and
mortality throughout the world. In developed countries, great progress has been made
to minimize the impact of chorioamnionitis, through timely diagnosis and appropriate
treatment. In the global setting, where many women deliver outside the healthcare
facilities, this diagnosis is frequently overlooked and not properly treated. In addition to
its impact on maternal health, a significant proportion of neonatal morbidity and mortality
can be prevented by both recognition and access to readily available treatment. With
the increasing focus on saving the most vulnerable members of society, we echo the
need for providing parturient women with suspected chorioamnionitis universal access to
appropriate therapy.We describe known effective antibiotic therapies for chorioamnionitis
and provide an overview of additional potential antimicrobial treatments that might be
effectively implemented in areas with limited access to care.
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Chorioamnionitis significantly contributes to maternal and neonatal poor outcomes. It represents
Intrauterine Infection and/or Inflammation (Triple-I) (Higgins et al., 2016). In the short-term,
chorioamnionitis can be associated with maternal sepsis, multi-organ dysfunction, stillbirth and
death. Among surviving newborns, chorioamnionitis is associated with asphyxia, and early onset
neonatal sepsis (EONS) well as long-term neurologic sequelae including cerebral palsy (Johnson
et al., 2014). Antibiotics have been the mainstay of intrapartum therapy, and proven to reduce
associated maternal and newborn morbidity. Chorioamnionitis can be clinically diagnosed by
the presence of maternal fever, prurulent discharge, and tachycardia in the mother or her
fetus (Higgins et al., 2016). Additional diagnostic methods include placental or amniotic fluid
evaluation, but havemore limited clinical applicability. Timely diagnosis and appropriate treatment
with empiric antibiotic therapy and fetal delivery improves maternal and neonatal outcomes.
Unfortunately, throughout the world, access to antibiotics and treatment for chorioamnionitis
is limited (Laxminarayan et al., 2016). A variety of antibiotics have been described for their use
in similar infections. We present a summary overview of current standard of care antimicrobial
therapy as well as additional antibiotics that can be considered to facilitate treatment in resource-
limited settings.
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MATERNAL AND NEONATAL MORBIDITY
ASSOCIATED WITH CHORIOAMNIONITIS
Chorioamnionitis, or Triple-I, is associated with significant
maternal morbidity including the need for cesarean delivery,
uterine atony, postpartum hemorrhage, as well as post-partum
wound infections (Johnson et al., 2014). Approximately, 1 in 30
deliveries is complicated by the presence of chorioamnionitis,
however the prevalence increases with decreasing gestational
age at the time of delivery and has been associated with an
estimated 25% of preterm deliveries (Ericson and Laughon,
2015). In the absence of treatment, up to 1 in 5 newborns
exposed to chorioamnionitis develop early onset neonatal sepsis
(Chan et al., 2015). Definitive treatment is achieved with delivery
of the uterine contents, while temporization with antibiotic
therapy may permit trial of labor and vaginal delivery rather
than immediate surgical cesarean delivery. Antibiotic therapy can
improve fetal signs of infection such as fetal tachycardia and
minimize some of the associated maternal morbidities (Johnson
et al., 2014). Therefore, while antibiotic therapy cannot eradicate
the infection, it is an important pillar of management to prevent
exacerbation of disease prior to delivery (Higgins et al., 2016).
Fetal sequelae from chorioamnionitis span from acute short-
term disease to life-long morbidities (Johnson et al., 2014). The
Fetal Immune Response Syndrome (FIRS) contributes to the
significant morbidity of the condition, suggesting that even with
antibiotic treatment of the offending organism, in some cases
the inflammatory response may still cause significant morbidity,
and is a major cause of stillbirth or neonatal death (Gibbs, 2002;
Kallapur et al., 2014). Early onset neonatal sepsis can result
in multi-organ dysfunction including life-threatening symptoms
of respiratory distress and hemodynamic instability, and can
be associated with chronic lung disease and neurologic injury
among survivors. These complications are exacerbated among
preterm infants and likely account for a significant proportion of
global neonatal mortality, with urgent need for research to better
delineate its impact are urgently needed (Lozano et al., 2012). It
is important to note that routine administration of antibiotics
in some cases of spontaneous preterm birth (e.g., preterm
premature rupture of membranes) has the potential to mitigate
neonatal sequelae (Cousens et al., 2010). Chorioamniontis in
the global setting is a potential cause of stillbirth (Gibbs,
2002). Therefore, proper diagnosis of chorioamnionitis, and
prompt administration of antibiotics to the laboring mother can
temporize management until delivery, or in some cases during
referral and triage to a tertiary care center and has the potential
to avert death and long-term morbidity in a significant number
of women and children (Gülmezoglu et al., 2016).
The burden of chorioamnionitis is most profound in Low
and Middle Income Countries (LMIC) (Chan et al., 2016).
Worldwide, an estimated 40 million births occur at home,
mostly in LMIC and usually in the absence of skilled birth
attendants and without access to proper preventative care as
well as diagnostics and proper treatment for possible infection
(Liu et al., 2016). A combination of poor conditions and poor
hygiene contribute to neonatal mortality, with evidence that
clean delivery practice has the potential to almost halve the risk
of neonatal mortality (Seward et al., 2012). Neonatal infections,
prematurity, and intrapartum related events account for the vast
majority of the neonatal deaths worldwide. In the presence of
overt chorioamnionitis, timely administration of antibiotics has
the potential to minimize the risk of overt maternal or fetal sepsis
(Chan et al., 2015) and has been associated with a 40% reduction
in the neonatal infectious sequelae (Tita and Andrews, 2010).
EXISTING GUIDELINES FOR TREATMENT
OF SUSPECTED CHORIOAMNIONITIS
General guidance for treatment for chorioamnionitis includes
antibiotic coverage of the causative pathogens (Higgins et al.,
2016). While widely subject to demographic and geographic
variability, common organisms associated with chorioamnionitis
include Ureaplasma (47%), Mycoplasma (30%), Gardnerella
vaginalis (25%), bacteriodes (30%), gram negative rods including
Escherichia Coli (8%), and Group B Streptococcus (15%) (Tita
and Andrews, 2010). GBS specifically has wide variability in
prevalence among global populations (Le Doare and Heath,
2013). The common feature of these organisms is that they
represent genital microbes that can ascend and cause a strong
inflammatory response.
Based on our knowledge of causative pathogens, a variety
of antibiotic regimens are used to cover the presumed
bacterial etiology of chorioamnionitis (Greenberg et al.,
2012). However, current consideration for antimicrobial
treatment for chorioamnionitis includes a combination of
an aminopenicillin and gentamicin, with clindamycin or
metronidazole generally added when cesarean delivery is
performed (Tita and Andrews, 2010; Higgins et al., 2016).
Of interest, neither antibiotic provides coverage against
mycoplasma, which is a common organism associated with
chorioamnionitis (Tita and Andrews, 2010). There are to date
limited randomized controlled trials to evaluate superiority of
antibiotic regimens to treat amniotic infections during ongoing
labor to demonstrate effectiveness (Chapman et al., 2014).
This suggests an absence of evidence basis for recommended
type of treatment for clinical chorioamnionitis in a limited
resourced setting. Therefore, current section of antibiotic
regimen is driven not by absolute science, but limitations
with existing research to demonstrate treatment superiority or
non-inferiority.
Treatment of chorioamnionitis is challenged by accurate
diagnosis, using clinical judgment in the assessment of signs of
maternal fever, maternal and/or fetal tachycardia, and purulent
cervical discharge (Johnson et al., 2014). Isolated maternal
fever may arise from other causes, and is not necessarily an
indication for diagnosis and treatment of chorioamnionitis
(Higgins et al., 2016). Diagnosis can also be made on histologic
placental evaluation after delivery, as well as microbial testing
of amniotic fluid, each with significant limitations regarding
clinical utility, particularly in a low resource setting (Johnson
et al., 2014). Additional, there appears to be imperfect
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TABLE 1 | A selected list of antibiotics and routes of administration, as included in the WHO guide of essential medications (WHO, 2016), with pregnancy
category, half-life, and indication of placental passage efficacy.
Antibiotic class Antibiotic Pregnancy category Route Half-life (hours) Placental transfer
Penicillins Benzyl PCN B Injection 0.5 Incomplete
Benzathine PCN G B Injection 30–50 Incomplete
PCN V B Oral 0.5 Incomplete
Procaine PCN G B Injection 20–40 Incomplete
Aminopenicillins Ampicillin B Injection 1 Complete
Amoxicillin B Oral 1.3 Complete
Penicillins: (Pellicinase Resistant) Cloxacillin B Oral, Injection 0.5 Incomplete
Cephalosporins Cefazolin B Injection 2 Complete
Cephalexin B Oral 1 Complete
Cephalosporins: Ceftriaxone B Injection 8 Complete
3rd Generation Cefotaxime B Injection 1 Complete
Ceftazidime B Injection 2 Complete
Vancomycin Vancomycin* C Injection 4–6 Incomplete
B-Lacatmase Inhibitors Amoxicillin/Clavulanate B Oral 1.0 Complete
Carbapenams Imipenam+Cilastin B Injection 1–2 Incomplete
Aminoglycosides Gentamicin C Injection 2–4 Incomplete
Macrolides Erythromycin B Oral, Injection 1–1.5 incomplete
Azithromycin B Oral 12 Incomplete
Clarithromycin C Oral 5–7 Complete
Chloramphenicol Chloramphenicol C Oral, Injection 1.2 Complete
Lincosamide Clindamycin* B Oral, Injection 2–3 Complete
Fluoroquinolones Ciprofloxacin C Oral, IV 3.7 Incomplete
Nitroimidazole Metronidazole Oral, injection, suppository 9 Complete
Nitroheterocylic Nitrofurantoin B Oral 0.33 Incomplete
Spectinomycin B Injection 2 Incomplete
Anti-Folate Agents Trimethoprim/Sulfa C Oral, Injection 12 Incomplete
Trimethoprim C Oral 12 Incomplete
Tetracycline Doxycycline D Oral 12–16 Complete
Adapted in part from Grayson et al. (2010), Roberts et al. (2008), and WHO (2016).
PCN, Penicillin.
*Indicates WHO complementary medication, to be considered for specific clinical circumstances.
correlation between these diagnostic methods (Chan et al., 2016).
Although chorioamnionitis is clearly associated with preterm
labor and delivery, the evidence does not support the routine
administration of antibiotics to women in preterm labor with
intact membranes in the absence of overt signs of infection, with
caution that such prophylaxis may exacerbate poor outcomes
(Subramaniam et al., 2012). Antibiotics for preterm premature
rupture of membranes are indicated and effective in reducing
the risk of a number of early morbidities, including respiratory
distress syndrome and infection, without having a significant
impact on mortality (Cousens et al., 2010). The burden of
neonatal disease due to Group B streptococcal infection has seen
dramatic improvement with standardized treatment following
universal screening in pregnancy (Koenig and Keenan, 2009).
It remains universally sensitive to penicillin, with alternative
antibiotic regimens considered only in cases of allergy. Therefore,
intrapartum antibiotics to prevent EONS are effective and have
reduced substantially the incidence of EONS in countries where
they are implemented (Dutta et al., 2010).
ADDITIONAL ANTIBIOTICS THAT CAN BE
CONSIDERED FOR TREATMENT OF
SUSPECTED CHORIOAMNIONITIS
A number of antibiotics might be considered for use in
pregnancy to treat amniotic infection, appreciating those listed
in the WHO Guide of Essential Medications (Table 1) (WHO,
2016). Considering fetal organ immaturity and/or ongoing organ
development, initial evaluation must consider potential fetal
organ toxicity or teratogenic effects, even when given just prior
to delivery. It is important to note, that while pregnancy category
may not strictly contradict administration, other considerations
might preclude their use as with fluoroquinolones (ACOG, 2016).
Secondary considerations would include route of administration.
This would be particularly relevant for developing regimens that
can be implemented in LMIC. Therefore, many of these agents
would be reasonable potential candidates in LMIC. As challenges
remain in recommendation of superior treatment regimens for
chorioamnionitis when compared to others, consideration of
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FIGURE 1 | A pictorial description of the factors that are needed for implementation of a policy for antibiotic therapy for chorioamnoninits into a
society where it is otherwise not accessible.
a variety of agents might be considered to provide effective
treatment for chorioamnionitis in a low resource setting.
Consideration of Trimethoprim/Sulfa for use is considered
in light of potential association with kernicterus in neonates
(Thyagarajan and Deshpande, 2014).
The WHO list of essential medications provides guidance
on a number of antibiotics that are most safe, efficacious, and
cost-effective for priority conditions (WHO, 2016). Potential
candidates for antibiotic therapy included on this list are further
described with their half-life as well as relevant pharmacokinetic
data on placental cross over (Table 1). Although treatment for
chorioamnionitis before delivery tends to leave a short interval
prior to delivery, duration of medication in case of needed
repeat dosing may be considered. Given that chorioamnionitis
represents an intra-amniotic infection, consideration of placental
transmission of the medication would seem relevant. For each
medication, individual considerations should be taken into
account among other factors. Such factors include the compound
stability, ease of administration, and medication cost, all of
which are considered in the creation of the WHO list of
essential medications. These factors may largely depend on
geographic or local factors specific to communities. Additionally,
medications that require weight-based considerations for dosing,
such as aminoglycosides, macrolides, or vancomycin, might
be challenging to implement. B-lactam antibiotics warrant
consideration for increased dosing for particularly obese patients,
which might be considered where obesity is a particular issue
(Pevzner et al., 2011). Cultural acceptability of a regimen is
important prior to implementation.
Accepted therapeutic regimens including ampicillin and
gentamicin have similar antibiotic coverage compared to
extended B-Lactamase agents (e.g., ampicillin/sulbactam). While
multiple agents permit extended coverage, single agent regimens
would seem to at least provide a modicum of convenience if
not pragmatic integration in lower resource areas. Oral agents
would have to consider their onset to action and bio-availability
relative to IM or IV dosing, as time-conscious treatment
of chorioamnionitis remains important. IV dosing will have
pragmatic limitations in most communities. Cost will also have
significant implications for universal provision, which would
contribute to considering one agent over another.
STEPS TO IMPLEMENTATION OF
UNIVERSAL TREATMENT FOR
CHORIOAMNIONITIS
Globally, there remains an unmet need of intrapartum treatment
of chorioamnionitis. Many steps will be made before this need
can be met. Antibiotic therapy will need to be affordable,
transportable, and readily administered. In addition, regimens
will need to demonstrate non-inferiority to standardized
regimens. Universal birth attendance is an unmet goal in many
LMIC. As efforts bend to millennium development goals help
improve the safety of childbirth, attention will move to significant
causes of morbidity such as chorioamnionitis. Just as with
uterotonics for postpartum hemorrhage and magnesium for
seizure prophylaxis, antibiotic therapy for intrapartum infection
will be necessary to reduce the morbidity of childbirth.
Attempts to create implementable regimens in various
regions will rely on multiple factors for implementation
(Figure 1). Evaluation of simplified regimens will be necessary to
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demonstrate effective policies but also to encourage widespread
implementation of effective treatment modalities (Zaidi et al.,
2013). Effective implementation of antibiotic therapy for
chorioamnionitis will require continued success with Sustainable
Development goals aiming to promote well-being for mothers
and children. Public Health efforts to minimize the maternal
and neonatal morbidity associated with chorioamnionitis will
continue. As attention is directed toward areas where treatment
is not currently available, those pregnancies in low resource
settings will benefit. As much focus as will need to be put on
birth attendance and appropriate delivery hygiene, provision of
appropriate antibiotic therapy for chorioamnionitis will remain
important.
CONCLUSIONS
Various antibiotics and classes of antibiotics may be
considered for effective treatment of chorioamnionitis. Ethical
demonstration of benefit is problematic, given that a number
of agents have long been considered effective therapy (Higgins
et al., 2016). We outline a number of different antibiotic
types that might be considered when developing treatment
algorithms for chorioamnionitis, particular in LMIC were
current treatment is far less than what a population might
need to minimize maternal and neonatal complications.
Effective treatment of chorioamnionitis will require more
than just antibiotic therapy; it will require a birth companion
competent to diagnose and treat the condition, an infrastructure
to provide such antibiotics to the appropriate providers. As
global efforts to increase the safety of birth advance, there is
an urgent need for antibiotic therapy to appropriately manage
chorioamnionitis in order to optimize maternal and neonatal
outcomes.
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